At GSK, I owned strategy and governance for the Agentic AI Portfolio Initiative, scaling AI and automation use cases that delivered $1.5M in cost savings and 30% process efficiency. I also designed D-TRAC, using enterprise GPT to standardise issue mitigation plans and predict potential risk causes.
At Biocon Biologics, I managed a INR 500 Cr portfolio and headed go-to-market strategy for three national launches. The launches achieved 25% faster market penetration, while omnichannel campaigns delivered a 30–35% ROI uplift.
At Eli Lilly and Company, I owned the global MLR process transformation, reducing cycle time by 20% and improving compliance outcomes by 30%. Across pharma R&D, commercial, medical and regulatory work, I’ve combined transformation, AI strategy and portfolio governance to deliver measurable business outcomes.

